Two high-priority medicine safety alerts — 14 September 2026

Regulators in the United States and Australia have published two high-priority medicine-safety alerts. The updates concern a nationwide recall of compounded injectable products after elevated bacterial endotoxin results and a counterfeit product sold as retatrutide that caused a serious adverse event.

United States: Centric Compounding recalls six injectable lots

Centric Compounding is recalling six lots of Glutathione 200 mg/mL, Myer’s Cocktail and Tri-Immune Boost injectable products to the consumer level. Testing identified elevated bacterial endotoxin levels in the glutathione active ingredient. Exposure may cause fever, hypotension, inflammatory reactions, anaphylactic shock and death. Nine adverse-event reports had been received. Patients and healthcare professionals should stop using and dispose of affected vials.

Official FDA recall notice

Australia: counterfeit “retatrutide” linked to serious injury

The TGA investigated a product sold as retatrutide after a consumer experienced uncontrollable vomiting, a torn oesophagus and hospitalisation. Laboratory testing found no retatrutide; instead, the vial contained undeclared semaglutide at approximately eight times the concentration of registered products. Retatrutide is not approved by the TGA or comparable regulators. Consumers should not use products claiming to contain retatrutide outside clinical trials, particularly unlabelled vials bought online or overseas.

Official TGA safety alert